NCT04102124 2025-06-24
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
Clinical Trials
7 trialsNCT06971211 2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2 Recruiting
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04691804 2024-12-31
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT04535687 2023-06-13
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT02747342 2020-07-21
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
Atridia Pty Ltd.
Phase 1 Completed